Is Intensity Therapeutics going out of business?

INTENSITY THERAPEUTICS, INC. (INTS) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

INTENSITY THERAPEUTICS, INC. (INTS) scores 22 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Filing event risk: Going-Concern Warning (-8 pts)

Five questions, kept separate

Survival - Fragile

6-9 mo of estimated runway from 2026-06-30, based on $9.5M of cash and short-term investments against $15.2M of annual burn. A disclosed filing event caps this reading; Event Risk carries the detail.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Undemanding

88.1% net-cash backing support an undemanding pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 3 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Debt / Equity: -1.02x (Net Cash)
• Filing event risk: Going-Concern Warning (-8 pts)
• Return on Assets: -100.74%
• Price / Earnings: Unprofitable (see Valuation)

Read from filings through 2026-08-11.

Price as of 2026-09-07.